Cholesterol guideline, vitamin D, REDUCE-IT and lipoprotein(a)
If you couldn’t make it to the American Heart Association’s (AHA) Scientific Sessions in Chicago this month, Cleveland Clinic Cardiovascular Medicine Chair Steven Nissen, MD, has got you covered. He recaps in the video below several of the most important presentations and other developments.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
He starts by sharing the many things to like about the new 2018 guideline on blood cholesterol management from the AHA and other societies — along with the one criticism he has of it. Then he explains why three studies presented at the meeting — the huge VITAL trial of vitamin D and omega-3, the controversial REDUCE-IT study of icosapent ethyl for hypertriglyceridemia, and a striking phase 2 study of a novel therapy for lowering lipoprotein(a) — are well worth knowing about.
Advertisement
Advertisement
A sampling of outcome and volume data from our Heart & Vascular Institute
Concomitant AF ablation and LAA occlusion strongly endorsed during elective heart surgery
Large retrospective study supports its addition to BAV repair toolbox at expert centers
Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy
Surprise findings argue for caution about testosterone use in men at risk for fracture
Residual AR related to severe preoperative AR increases risk of progression, need for reoperation
Findings support emphasis on markers of frailty related to, but not dependent on, age
Provides option for patients previously deemed anatomically unsuitable